Cargando…
Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies
Anti-drug antibodies induced by biologic therapeutics often impact drug pharmacokinetics, pharmacodynamics response, clinical efficacy, and patient safety. It is critical to assess the immunogenicity risk of potential biotherapeutics in producing neutralizing and nonneutralizing anti-drug antibodies...
Autores principales: | Partridge, Michael A., Purushothama, Shobha, Elango, Chinnasamy, Lu, Yanmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983396/ https://www.ncbi.nlm.nih.gov/pubmed/27556048 http://dx.doi.org/10.1155/2016/6262383 |
Ejemplares similares
-
Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development
por: Lu, Yanmei, et al.
Publicado: (2016) -
REGEN-COV(®) antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification
por: Irvin, Susan C, et al.
Publicado: (2021) -
Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs
por: Glerum, Pieter J., et al.
Publicado: (2018) -
Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance
por: Collet-Brose, Justine, et al.
Publicado: (2016) -
Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain
por: Johnson, Derrick, et al.
Publicado: (2021)